FDA Should Call Last Round For OTC Hangover Indication, Cmte. Suggests

 
• By Malcolm Spicer

Comments from the Nonprescription Drug and the Drug Safety and Risk Management advisory committees during a joint meeting could push US FDA toward pulling the plug on hangover as a monograph indication.

Including hangover as an indication for OTC monograph drugs could be more problem than remedy by contributing to misuse of antacid/analgesic and aspirin/caffeine nonprescription products, an FDA advisory panel concludes.

Comments from members of the Nonprescription Drug and the Drug Safety and Risk Management advisory committees during a joint meeting of April 4 could push

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America